What To Look Out For In Glioblastoma At ASCO
Executive Summary
Bristol-Myers Squibb, Tracon Pharmaceuticals and Ziopharm are slated to present promising early data in glioblastoma at upcoming ASCO meeting.
You may also be interested in...
Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?
The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.